DisclosureWe earn commission on partner links; ranking is set by our evidence-based methodology — not advertisers. Read policy
Tru Niagen delivers patented nicotinamide riboside (Niagen) to support cellular NAD+ levels, marketed as a daily foundational supplement for healthy aging.
A safe NAD+ booster with thin proof of payoff
Tru Niagen does what it claims at the biochemical level: in a randomized, placebo-controlled trial, 300mg daily raised whole-blood NAD+ by roughly 51% within two weeks, and the ingredient has one of the deepest safety dossiers of any longevity supplement. The catch is that raising NAD+ has not translated into proven anti-aging outcomes (energy, strength, metabolism, or lifespan) in controlled human trials. It is a low-risk bet for biohackers comfortable paying for a biomarker change without guaranteed felt benefits.
We may earn a commission if you buy through this link, at no extra cost to you. It never affects our score. How we make money
Tru Niagen is the consumer supplement brand for Niagen, a patented and FDA-reviewed form of nicotinamide riboside chloride (NR) — a vitamin-B3 derivative that the body converts into nicotinamide adenine dinucleotide (NAD+). It is sold by Niagen Bioscience (Nasdaq: NAGE), the company previously known as ChromaDex, which holds the core patents and licenses on Niagen and funds much of the published research on the ingredient.
The standard product is a once-daily 300 mg vegetarian capsule. The company also sells a higher-dose Tru Niagen Pro 1,000 mg line aimed at people who want a larger NAD+ increase. NR was discovered as a NAD+ precursor in the lab of biochemist Charles Brenner, whose group published the first human pharmacokinetic study of the molecule (PMID 27721479, *Nature Communications* 2016).
It is worth naming the central conflict of interest up front: the manufacturer sponsors or co-authors a large share of the human trials on Niagen. The trials are real, peer-reviewed, and mostly well-designed, but readers should weigh industry funding when interpreting how findings are framed.
NAD+ is a coenzyme present in every living cell. It is essential for converting food into cellular energy (it shuttles electrons in the mitochondria), and it is consumed as a substrate by repair and signaling enzymes such as the sirtuins and PARPs that respond to DNA damage and metabolic stress. NAD+ levels in tissues are widely reported to decline with age and with metabolic stress, and the core hypothesis behind every NAD+ supplement is simple: if you replenish the precursor, you raise NAD+, and higher NAD+ might restore some age-related decline in cellular function.
Nicotinamide riboside is one of several precursors the body can use to build NAD+ through the salvage pathway. Niagen Bioscience's key bioavailability argument is that NR enters cells and is converted to NAD+ efficiently. The first-in-human study showed that single oral doses of 100, 300, and 1,000 mg produced dose-dependent increases in the blood NAD+ metabolome, and identified a metabolic signature (NAAD) confirming NR was being used to build NAD+ (Trammell et al., *Nature Communications* 2016, PMID 27721479).
The important caveat: raising blood NAD+ is the mechanism, not the outcome. A supplement can robustly move a biomarker without changing how you feel or how your body ages. That distinction runs through the rest of this review.
This is where the data are genuinely good. Multiple randomized, double-blind, placebo-controlled trials show Niagen reliably and substantially increases whole-blood NAD+.
The most informative is a randomized, double-blind, placebo-controlled trial in 140 healthy overweight adults aged 40–60 (133 completed) testing 100, 300, and 1,000 mg/day for eight weeks (Conze, Brenner & Kruger, *Scientific Reports* 2019, PMID 31278280). At day 14, blood NAD+ rose by roughly 22% at 100 mg, 51% at 300 mg, and 142% at 1,000 mg, and the increases were sustained through day 56. This is the basis for the brand's "increase NAD+ by over 50%" claim, which maps to the 300 mg dose.
An earlier randomized crossover trial in healthy middle-aged and older adults also found that 1,000 mg/day was well tolerated and reliably elevated NAD+ (Martens et al., *Nature Communications* 2018, PMID 29599478). Across the published literature, the bioavailability story is consistent: NR gets into the blood and raises NAD+ in a dose-dependent way.
So if your only question is "does it move the biomarker it claims to move?", the answer is clearly yes.
This is the honest weak point, and it is where independent analysis diverges most sharply from marketing.
For healthy people, the clinical evidence that higher NAD+ improves anything you would actually notice is limited and frequently null. The same 2018 crossover trial that confirmed NAD+ elevation reported a modest reduction in systolic blood pressure and aortic stiffness in a subgroup, but these were exploratory secondary findings, not a primary endpoint, and have not been robustly replicated. Critically, several rigorous trials designed specifically to test metabolic benefit have come back negative:
The 2019 trial in 140 overweight adults likewise found NAD+ went up but reported no significant differences versus placebo in blood pressure, lipids, or clinical chemistry parameters over eight weeks (PMID 31278280).
There are more promising signals in specific patient populations — for example, manufacturer-supported work suggesting NR can reduce markers of inflammation, and early-phase trials in Parkinson's disease showing high-dose NR raises brain and blood NAD+ with hints of symptom benefit. But these are early, mostly small, and not the same thing as proving that a healthy 50-year-old who takes 300 mg a day will live longer, feel more energetic, or age more slowly.
Bottom line on efficacy: strong evidence it raises NAD+, weak-to-mixed evidence it changes meaningful health outcomes in healthy adults. There is currently no published long-term human trial demonstrating that NR slows aging or extends healthspan.
Safety is the most reassuring part of the profile. Across trials, NR has been well tolerated, with adverse-event rates generally comparable to placebo and, notably, without the skin flushing caused by high-dose niacin (nicotinic acid). In the 140-person trial, the type, incidence, and severity of adverse events were similar across all doses and placebo (PMID 31278280). Higher doses up to 1,000–2,000 mg/day in trials have also been tolerated, and a Parkinson's study used 3,000 mg/day short-term.
When side effects occur they are usually mild and gastrointestinal — nausea, bloating, or stomach discomfort — plus occasional headache or fatigue.
On regulation, Niagen has an unusually clean paper trail for a supplement ingredient:
Important real-world caveats:
The standard, evidence-anchored dose is 300 mg once daily — one capsule — which is the dose tied to the ~50% NAD+ increase. It can be taken with or without food; there is no strong evidence that timing matters, though some people take it in the morning. Tru Niagen Pro provides 1,000 mg for those targeting the larger (~142%) NAD+ increase seen in trials, but there is no good evidence that the larger NAD+ rise produces proportionally larger health benefits — so paying more for a bigger biomarker move is not clearly worth it for most healthy people.
NAD+ elevation appears within about two weeks of consistent daily use and is sustained with continued dosing. If you stop, levels return toward baseline.
At the manufacturer's listed prices, the 300 mg, 30-capsule bottle is about $49 (roughly $1.63/day), with larger bottles and a 20% subscription discount lowering that meaningfully:
Prices on Amazon and through the official site vary, so check current listings. (Prices reflect the manufacturer's published figures and can change.)
Value verdict: You are paying a premium for the patented, clinically studied, third-party-clean ingredient and the strongest body of bioavailability data in the category. That premium buys confidence in *quality and NAD+ elevation*, not proof of a health payoff. Whether ~$1–1.60/day is "worth it" depends entirely on how much you value moving a biomarker whose downstream benefit in healthy people is still unproven.
The main rival precursor is nicotinamide mononucleotide (NMN), heavily promoted in longevity circles. The two have a notable regulatory history: in November 2022 the FDA took the position that NMN was excluded from the supplement definition because it had been authorized for investigation as a drug. After an industry citizen petition and litigation, the FDA reversed course in 2025, concluding NMN qualifies as a dietary supplement ingredient (FDA letters, 2025; reported by NutraIngredients). The practical takeaway for buyers: NR (Niagen) has had a stable, well-documented regulatory status throughout, while NMN's status was contested for years.
On the science, the honest summary is that head-to-head human evidence that either precursor is clinically superior does not exist. Niagen Bioscience argues NR is more directly bioavailable; NMN proponents argue the reverse. Both raise NAD+ in humans; neither has proven a meaningful healthspan benefit in healthy people. Tru Niagen's genuine differentiators are the patent protection, FDA/EFSA/TGA regulatory clearances, and the largest published human trial base in the category — which matter for trusting what is in the bottle, even if they do not settle the efficacy question.
Cheaper generic NR and NMN powders exist, but they lack Niagen's IP, regulatory dossier, and (often) third-party purity verification, which is a real consideration in a supplement market with documented quality and label-accuracy problems.
Reasonable candidates:
Who should probably skip it:
Tru Niagen is the most rigorously studied, cleanly regulated NAD+ booster on the market, and it does exactly what it most concretely promises: a daily 300 mg dose reliably raises blood NAD+ by roughly 50% within two weeks (PMID 31278280). That is a real, replicated effect, and the safety record over weeks-to-months is reassuring (FDA GRAS; EFSA Novel Food).
What it has not demonstrated is that raising NAD+ produces the anti-aging, energy, or metabolic improvements that drive most purchases — several well-designed trials in healthy and metabolically impaired adults found no benefit beyond the biomarker change, and there is no long-term human healthspan trial. If you understand and accept that you are buying a high-quality way to move a biomarker rather than a proven anti-aging intervention, Tru Niagen is a defensible, low-risk choice. If you want evidence that it will make you healthier, the science is not there yet.
Tru Niagen delivers Niagen, a patented form of nicotinamide riboside (NR), a relative of vitamin B3. Your cells convert NR into NAD+ (nicotinamide adenine dinucleotide), a coenzyme essential for turning food into cellular energy, supporting DNA repair, and fueling the activity of enzymes called sirtuins. NAD+ levels tend to decline with age, and the theory is that replenishing NAD+ may support healthier cellular aging. Importantly, the supplement reliably raises blood NAD+; whether that higher NAD+ produces meaningful health benefits in people is still an open question.
Active ingredient: Nicotinamide riboside
The strongest, most consistent finding is at the biomarker level: in a randomized, double-blind, placebo-controlled trial of 140 overweight but otherwise healthy adults (Conze et al., 2019), Niagen raised whole-blood NAD+ dose-dependently within two weeks (about 22% at 100mg, 51% at 300mg, and 142% at 1000mg per day), and the increase was sustained over the 8-week study. Downstream clinical benefits are far less convincing. Dollerup et al. found that NR (1000mg twice daily, 2000mg/day for 12 weeks) raised NAD+ but did not meaningfully improve insulin sensitivity, skeletal-muscle mitochondrial function, or body composition in obese, insulin-resistant men. A 2018 crossover trial in middle-aged and older adults (Martens et al., 1000mg/day) raised NAD+ by roughly 60% but found that reductions in blood pressure and aortic stiffness did not reach statistical significance. So NR clearly elevates NAD+; the evidence that it slows aging or improves performance in healthy people remains weak.
A realistic timeline of what Tru Niagen users typically experience. Individual results vary; this is educational, not medical advice.
You start one capsule (300 mg) daily, with or without food. There's no loading or titration phase. Tru Niagen is a supplement, not a drug, so you won't feel an acute 'dose' effect; the change happens at the cellular level. Set a daily reminder, since consistency matters more than timing.
Blood NAD+ begins rising quickly. In Chromadex's randomized trial of Niagen, daily 300 mg and 1000 mg doses significantly raised whole-blood NAD+ within 7 days. This is a measurable internal change, not something you'll necessarily feel yet, and most people notice nothing subjective in the first week.
NAD+ reaches a meaningful elevation and stabilizes. The same trial showed ~51% higher NAD+ at 300 mg (and ~142% at 1000 mg) by week 2, and levels appear to hit a new steady state by about week 4. Some users start reporting subtle changes in energy, focus, or sleep here, but these are self-reported and inconsistent. Genuinely give it a fair trial before judging.
This is the realistic window to evaluate whether it's doing anything noticeable for you. A 2025 Lancet long-COVID RCT found NAD+ up ~2.6-fold at 5 weeks and ~3.1-fold at 10 weeks. Subjective benefits reported by users (energy, recovery, mental clarity) cluster in this period, but results vary widely and a sizable share of people, especially those who are younger and healthier, report no perceptible change at all.
If you continue, NAD+ stays elevated as long as you keep taking it daily; effects are not cumulative beyond the established plateau and decline once you stop. Long-term human trials (up to 8-12 weeks, with safety data extending further) found the safety profile similar to placebo, with no flushing and only mild, transient side effects (occasional nausea or muscle soreness). Niagen does not treat or cure any disease; discuss ongoing use with your clinician, especially if pregnant, nursing, or on medication.
Across trials at doses up to 1000-2000mg/day, Niagen has been well tolerated, with adverse-event rates similar to placebo and, notably, no skin flushing (a common complaint with older high-dose niacin). In real-world use, mild and transient effects can include nausea, stomach discomfort, bloating, headache, or fatigue. No serious adverse events have been clearly attributed to NR in published trials. Long-term safety beyond a few months is less studied, and because NAD+ influences cell metabolism, people with cancer or other proliferative conditions should be cautious and consult a physician before use.
Starts at $40/mo from Tru Niagen.
As of 2026, Tru Niagen 300mg costs $49 for a 30-count bottle (about one month) at full price directly from the manufacturer, or $39.20/month on subscription (20% off, with free shipping). Larger bottles lower the per-capsule cost: a 90-count is $127 ($101.60 on subscription) and a 180-count is $244 ($195.20 on subscription), which works out to roughly $1.08-$1.41 per day depending on size and whether you subscribe. At higher daily doses, monthly cost rises proportionally. As a dietary supplement it is not covered by insurance and rarely qualifies for HSA/FSA reimbursement without a doctor's letter. Third-party retailers (Amazon, Costco, Walmart) sometimes price below MSRP.
Prices current as of May 29, 2026 and exclude promo codes; cash-pay and channel pricing change frequently — confirm with the pharmacy or provider.
If your goal is a clinically documented, well-tolerated way to elevate NAD+, Tru Niagen is among the most credible options on the market, backed by dozens of clinical studies and FDA GRAS no-objection status. If your goal is to feel younger, sleep better, or measurably improve metabolism, the human evidence does not yet support those promises, and much of the supporting research is tied to the ingredient maker. Buy it for the documented biochemistry and the safety record, not for guaranteed results.
It works at the biochemical level: in a randomized, placebo-controlled trial, 300mg daily raised whole-blood NAD+ by about 51% within two weeks. But human studies have not proven that this NAD+ boost produces felt benefits like more energy, better metabolism, or slower aging, so 'works' depends on whether you mean the biomarker or the outcome.
No supplement is FDA-approved. Tru Niagen's Niagen ingredient has received FDA GRAS (Generally Recognized as Safe) no-objection status (GRN 635) and two New Dietary Ingredient notifications, which address safety, not proof of anti-aging effectiveness. The FDA does not evaluate supplements for efficacy before sale.
It is generally well tolerated, with trial adverse-event rates similar to placebo and no flushing. Mild, occasional effects can include nausea, stomach upset, bloating, headache, or fatigue. No serious side effects have been clearly linked to it in published trials, though long-term (multi-year) safety is not well studied.
The standard and evidence-backed dose is one 300mg capsule daily, the amount shown to raise blood NAD+ by roughly 51% in a randomized trial. The label allows up to three capsules (900mg) daily, and the ingredient has been studied as safe at up to 2,000mg/day for several weeks. Take it at the same time each day for consistency.
As of 2026, a 30-day bottle of Tru Niagen 300mg costs $49 at full price or $39.20/month on subscription (20% off) with free shipping. Larger 90-count ($127) and 180-count ($244) bottles lower the per-day cost. It is not covered by insurance and rarely qualifies for HSA/FSA without a doctor's letter.
It is worth it if you specifically want a safe, well-studied way to raise NAD+ and accept that downstream benefits are unproven. If you expect guaranteed energy, anti-aging, or metabolic improvements, the human evidence does not yet justify the roughly $39-$49 monthly cost. It is best viewed as a low-risk biochemistry bet, not a results guarantee.
It targets a mechanism linked to aging (declining NAD+), but no human trial has shown that it extends lifespan or measurably slows aging. The longevity case is theoretical and based on a biomarker change (higher NAD+), not on demonstrated outcomes. Talk to a clinician before relying on any supplement for healthy aging.
Avoid it if you are pregnant or breastfeeding (it is untested in these groups), and consult a doctor first if you have cancer or a cancer history, kidney or liver disease, or take prescription medications. It is not intended for children. As with any supplement, clear it with your clinician if you have a chronic health condition.
Tru Niagen (NR) and NMN both raise NAD+, and neither has proven outcome benefits in humans; NR has more published human safety data and FDA clearances. NMN's US supplement status was contested after the FDA excluded it in 2022, but the agency reversed course in 2025 and now considers NMN lawful in supplements. Unlike high-dose niacin, NR causes no flushing.
Affiliate link — we may earn a commission at no extra cost to you, and it never changes our rankings or score. Disclosure
Same-category options, scored on the same six-axis rubric. Higher is better.